DOCSLIB.ORG

Genito-Urinary and Sex Hormone Drug Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genito-Urinary and Sex Hormone Drug Poster Genito-Urinary and Sex Hormone Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson DES Estinyl Dienestrol Chloromycetin Tace Regitine Delatestryl Delestrogen Halotestin Furoxone Provera Clomifene Duphaston Flagyl Terramycin Tham Mycostatin ( Diethylstilbestrol ) ( Ethinyl Estradiol ) ( Dienestrol ) ( Chloramphenicol ) ( Chlorotrianisene ) ( Phentolamine ) ( Testosterone ) ( Estradiol ) ( Fluoxymesterone ) ( Furazolidone ) ( Medroxyprogesterone ) ( Clomifene ) ( Dydrogesterone ) ( Metronidazole ) ( Oxytetracycline ) ( Dinoprostone ) ( Nystatin ) SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS GYN. ANTIINFECTIVE & ANTISEPTIC GYN. ANTIINFECTIVE & ANTISEPTIC OTHER GYNECOLOGICALS GYN. ANTIINFECTIVE & ANTISEPTIC Approved 1940 Approved 1943 Approved 1947 Approved 1950 Approved 1950s Approved 1952 Approved 1953 Approved 1954 Approved 1956 Approved 1958 Approved 1959 Approved 1960s Approved 1961 Approved 1963 Approved 1964 Approved 1965 Approved 1965 Fungizone Cleocin Demulen 1/35(21) Urispas Vanobid Megace Motrin Lotrimin Ditropan Naprosyn Progestasert Parlodel Premarin Rimso-50 Natacyn Hemabate Estrone ( Amphotericin B ) ( Clindamycin ) ( Ethinyl Estradiol & Ethynodiol Diacetate ) ( Flavoxate ) ( Candicidin ) ( Megestrol ) ( Ibuprofen ) ( Clotrimazole ) ( Oxybutynin ) ( Naproxen ) ( Progesterone ) ( Bromocriptine ) ( Conjugated Estrogens ) ( Dimethyl Sulfoxide ) ( Natamycin ) ( Carboprost ) ( Estrone ) GYN. ANTIINFECTIVE & ANTISEPTIC GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS GYN. ANTIINFECTIVE & ANTISEPTIC UROLOGICAL AGENT OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS Approved 1966 Approved 1970 Approved 1970 Approved 1970 Approved 1970s Approved 1971 Approved 1974 Approved 1975 Approved 1975 Approved 1976 Approved 1976 Approved 1978 Approved 1978 Approved 1978 Approved 1978 Approved 1979 Approved 1979 Desogestrel Prostin VR Pediatric Nizoral Loprox Spectazole Lithostat TZ-3 MS Contin Femstat Ritodrine Hytrin Terazol 7 Oxistat Norplant Norgestimate Prepidil Proscar ( Desogestrel ) ( Alprostadil ) ( Ketoconazole ) ( Ciclopirox ) ( Econazole ) ( Acetohydroxamic Acid ) ( Tioconazole ) ( Morphine ) ( Butoconazole ) ( Ritodrine ) ( Terazosin ) ( Terconazole ) ( Oxiconazole ) ( Levonorgestrel ) ( Norgestimate ) ( Dinoprostone ) ( Finasteride ) SEX HORMONES & MODULATORS UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC GYN. ANTIINFECTIVE & ANTISEPTIC GYN. ANTIINFECTIVE & ANTISEPTIC UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC OTHER GYNECOLOGICALS UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS UROLOGICAL AGENT Approved 1980s Approved 1981 Approved 1981 Approved 1982 Approved 1982 Approved 1983 Approved 1983 Approved 1984 Approved 1985 Approved 1987 Approved 1987 Approved 1987 Approved 1988 Approved 1990 Approved 1990s Approved 1992 Approved 1992 Fosamax Ethyol Miacalcin Prempro & Premphase Arimidex Dostinex Taxotere Eulexin Monurol Zoladex Lupron Depot Estrostep Aredia Hycamtin Fertinex Gonal-F Follistim ( Alendronate ) ( Amifostine ) ( Calcitonin ) ( Conjugated Estrogens & Medroxyprogesterone Acetate ) ( Anastrozole ) ( Cabergoline ) ( Docetaxel ) ( Flutamide ) ( Fosfomycin ) ( Goserelin ) ( Leuprolide ) ( Norethindrone Acetate & Ethinyl Estradiol ) ( Pamidronate ) ( Topotecan ) ( Urofollitropin ) ( Follitropin Alfa ) ( Follitropin Beta ) SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1997 Approved 1997 Sporanox Femara Alesse Ortho Tri-Cyclen Floxin Evista Flomax Norethin 1/50m-21 Mircette Herceptin Lisuride Viagra Detrol Doxil Ellence Prefest Aromasin ( Itraconazole ) ( Letrozole ) ( Levonorgestrel & Ethinyl Estradiol ) ( Norgestimate & Ethinyl Estradiol ) ( Ofloxacin ) ( Raloxifene ) ( Tamsulosin ) ( Estranol & Norethindrone ) ( Ethinyl Estradiol & Desogestrel ) ( Trastuzumab ) ( Lisuride ) ( Sildenafil ) ( Tolterodine ) ( Doxorubicin ) ( Epirubicin ) ( Estradiol & Norgestimate ) ( Exemestane ) UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS UROLOGICAL AGENT UROLOGICAL AGENT OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1999 Approved 1999 Approved 1999 Approved 1999 Plan B Calcium Chloride Cetrotide Activella Ovidrel Mifeprex Trelstar Depot Yasmin Avodart Invanz Nuvaring Bextra Zoloft Forteo Plenaxis Uroxatral Climara Pro ( Norgestrel ) ( Calcium Chloride ) ( Cetrorelix ) ( Estradiol & Norethindrone Acetate ) ( Choriogonadotropin Alfa ) ( Mifepristone ) ( Triptorelin ) ( Drospirenone & Ethinyl Estradiol ) ( Dutasteride ) ( Ertapenem ) ( Ethinyl Estradiol & Etonogestrel ) ( Valdecoxib ) ( Sertraline ) ( Teriparatide ) ( Abarelix ) ( Alfuzosin ) ( Estradiol & Levonorgestrel SEX HORMONES & MODULATORS UROLOGICAL AGENT SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS UROLOGICAL AGENT SEX HORMONES & MODULATORS UROLOGICAL AGENT SEX HORMONES & MODULATORS UROLOGICAL AGENT GYN. ANTIINFECTIVE & ANTISEPTIC SEX HORMONES & MODULATORS OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS UROLOGICAL AGENT UROLOGICAL AGENT SEX HORMONES & MODULATORS Approved 1999 Approved 2000 Approved 2000 Approved 2000 Approved 2000 Approved 2000 Approved 2000 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2002 Approved 2003 Approved 2003 Approved 2003 Cialis Levitra Apokyn Enablex VESIcare Sanctura Angeliq Implanon Doribax Reclast Degarelix Cervarix Lysteda Jevtana Prolia Jalyn Halaven ( Tadalafil ) Vardenafil ( Apomorphine ) ( Darifenacin ) ( Solifenacin ) ( Trospium ) ( Drospirenone & Estradiol ) ( Etonogestrel ) ( Doripenem ) ( Zoledronic Acid ) ( Degarelix ) ( Human Papillomavirus Bivalent Vaccine ) ( Tranexamic Acid ) ( Cabazitaxel ) ( Denosumab ) ( Dutasteride & Tamsulosin ) ( Eribulin ) UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT UROLOGICAL AGENT SEX HORMONES & MODULATORS SEX HORMONES & MODULATORS UROLOGICAL AGENT OTHER GYNECOLOGICALS UROLOGICAL AGENT OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS UROLOGICAL AGENT OTHER GYNECOLOGICALS UROLOGICAL AGENT OTHER GYNECOLOGICALS Approved 2003 Approved 2003 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2005 Approved 2006 Approved 2007 Approved 2007 Approved 2008 Approved 2009 Approved 2009 Approved 2010 Approved 2010 Approved 2010 Approved 2010 Natazia Oravig Provenge Ella Zytiga Makena Stendra Xtandi Afinitor Myrbetriq Perjeta ( Estradiol Valerate & Dienogest ) ( Miconazole ) ( Sipuleucel-T ) ( Ulipristal Acetate ) ( Abiraterone Acetate ) ( Hydroxyprogesterone Caproate ) ( Avanafil ) ( Enzalutamide ) ( Everolimus ) ( Mirabegron ) ( Pertuzumab ) SEX HORMONES & MODULATORS GYN. ANTIINFECTIVE & ANTISEPTIC UROLOGICAL AGENT SEX HORMONES & MODULATORS UROLOGICAL AGENT OTHER GYNECOLOGICALS UROLOGICAL AGENT UROLOGICAL AGENT SEX HORMONES & MODULATORS UROLOGICAL AGENT OTHER GYNECOLOGICALS Approved 2010 Approved 2010 Approved 2010 Approved 2010 Approved 2011 Approved 2011 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 All drugs are considered FDA approved in the U.S. following the passage of the Pure Food and Drugs Act in 1906. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ * Initially approved outsides of the U.S..
Load more

Recommended publications
  • Fluoxymesterone-Dea Schedule Iii Androfluorene
    Cat. No. F7751 FLUOXYMESTERONE--DEA SCHEDULE III ANDROFLUORENE Androgen. OH Mol. Formula: C20H29FO3 HO H3C CH3 Mol. Wt.: 336.45 (anhyd.) F H3C m.p.: 288-290°C CAS Registry No.: 76-43-7 O Chemical Name: 4-Androsten-9a-fluoro-17a-methyl-11b,17b-diol-3-one 22 Physical Properties: White photosensitive solid. [a] D = +102.34° (c = 0.47, EtOH). Caution: Due care should be exercised to prevent skin contact, ingestion or inhalation of this compound. Storage: Store tightly sealed at room temperature, protected from exposure to light. Solubility: Soluble in ethanol (7.3 mg/ml) or water (< 0.5 mg/ml). Solubility in 45% aqueous (w/v) 2-hydroxypropyl-b- cyclodextrin (Cat. No. H-107): 6.4 mg/ml. Disposal: Dissolve or mix the compound with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. This product is controlled by the Drug Enforcement Administration. Appropriate security must be maintained until the substance is destroyed. Records must be kept which detail the ultimate disposition of the material. References: 1. Merck Index 11th Ed., No. 4113. 2. Saborido, A., Vila, J., Molano, F., Megias, A. “Effect of steroids on mitochondria and sarcotubular system of skeletal muscle.” J. Appl. Physiol. 70(3), 1038 (1991). 3. Fernandez, L., Chirino, R., Boada, L.D., Navarro, D., Cabrera, N., del Rio, I., Diaz-Chico, B.N. “Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes.” Endocrinology 134(3), 1401 (1994). CONTROLLED SUBSTANCE - DEA LICENSE REQUIRED (III) Rev.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • INTEGRIS Formulary July 2017
    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Anabolic Steroids/Androgens Pa Summary
    ANABOLIC STEROIDS/ANDROGENS PA SUMMARY PREFERRED Anadrol-50, Danazol, Fluoxymesterone, Methitest, Oxandrolone, Testosterone Cypionate Injection, Testosterone Enanthate Injection NON-PREFERRED Android, Testred LENGTH OF AUTHORIZATION: Varies NOTE: All preferred and non-preferred agents require prior authorization. See PA criteria labeled “Topical Testosterone” for Androderm, Androgel, Striant, and Testim. The criteria details below are for the outpatient pharmacy program. If an injectable medication is being administered in a physician’s office then the criteria information below does not apply. Instead, the physician’s office must bill this drug through the DCH physician’s injectable program and not the outpatient pharmacy program. Information regarding the physician’s injectable program can be located at www.mmis.georgia.gov. PA CRITERIA: For Anadrol-50 Approvable for the following diagnoses: anemia caused by deficient red blood cell production, acquired or congenital aplastic anemia, myelofibrosis, hypoplastic anemia due to administration of myelotoxic drugs Also approvable for HIV or AIDS wasting when significant weight loss is documented in members currently receiving nutritional support For Danazol Approvable for the following diagnoses: endometriosis, fibrocystic breast disease, hereditary angioedema For Fluoxymesterone, Methyltestosterone (Android, Methitest, Testred), Testosterone Cypionate or Enanthate Injection Approvable in male members 12 years of age or older for the following diagnoses: primary hypogonadism, secondary
    [Show full text]
  • Printed Formulary Catalog Basic
    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
    [Show full text]
  • Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole
    Research Article Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole Luciana F. Macedo, Zhiyong Guo, Syreeta L. Tilghman, Gauri J. Sabnis, Yun Qiu, and Angela Brodie Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore, Maryland Abstract hormone therapy and longer patient survival (14). However, the Previous work has shown that androgens inhibit breast cancer physiologic role of endogenous androgens and events following AR cells and tumor growth. On the other hand, androgens can be activation leading to inhibition of cell growth are not clearly identified in breast cancer cells. Some studies have shown that converted to mitogenic estrogens by aromatase in breast cancer cells. Here, we report that androgens, such as the androgens modulate the expression of the Bcl-2protein family in aromatizable androstenedione and the non-aromatizable breast cancer cells, and that their effect is contrary to that of 5A-dihydrotestosterone, inhibit MCF-7 cell proliferation. This estrogens (15, 16). The Bcl-2family proteins both inhibit and effect is observed only in the absence or at a low concentra- promote cell death (16, 17), and the Bcl-2protein has been tion of estrogens and is evident in cells with low aromatase extensively characterized as an inhibitor of apoptosis. activity. Growth of a new aromatase stably transfected MCF-7 Due to their adverse side effects, exogenous androgens were later cell line (Ac1) was stimulated by conversion of androstene- replaced by other better tolerated breast cancer treatment dione into estrogens and was sensitive to aromatase inhib- strategies, such as ER antagonism and aromatase inhibition.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Combined Cardiac Effect of the Anabolic Steroid, Nandrolone And
    ù1. v -¿. rlc) 77.- *n*hi.rnool oowol,ù*o ffi"/fu -lo *rn*(o fii'o fio¿o¿¿, /v&"ùún lonno **al cooaiæe';¿vfl"- oã. Benjamin D. Phillis, B.Sc. (Hons) Phatmacology Depattment of Clinical & Experimental Pharmacology Ftome Rd. , Medical School Noth Adelaide Univetsity ADEIAIDE SA 5OOO û.)r.'-*hr/7enveltîù Foremost, I would like to thank my two supervisors for the direction that they have given this ptojecr. To Rod, for his unfailing troubleshooting abiJity and to Jenny fot her advice and ability to add scientific rigour' Many thanks to Michael Adams for his technical assistance and especially fot performing the surgery for the ischaemia-reperfusion projects and for his willingness to work late nights and public holidays. Lastly I would like to thank my v¡ife for her extreme patience during the tumult of the last 5 years. Her love, suppoït, patience and undetstanding have been invaluable in this endeavout. Beniamin D. Phillis Octobet,2005 ADE,I-AIDE ii T*(¿t of Ao,t",tù DECI.ARATION I ACKNOWLEDGEMENTS il TABLE OF CONTENTS UI ABBREVIATIONS x ABSTRACT )ilr CÉIAPTER t-l Inttoduction 1-1 1.1 Background 1,-1, 1.2What ate anabolic stetoids? 7-1 1,3 General pharmacology of Anabolic steroids t-2 '1,-2 1.3.1 Genomic effects of anabolic steroids 1.3.2 Non-genomic effects of anabolic steroids 1-3 1.4 Clinical use of AS 1.-4 1.5 Patterns of AS abuse 1.-4 1.5.1 Steroid abuse by athletes 1.-+ 1.5.2 Stetoid abuse by sedentary teenagers r-6 1.5.3 Prevalence of abuse 1-6 1.5.4 Abuse ptevalence in Australia 1.-9 1.6 Cardiotoxicity of anabolic steroids r-9 1.6.1 Reduced cotonary flow 1.-1.1, 1,.6.2 Dtect myocatdial eff ects 1-1 5 1.6.3 Hypertension 1-21 1.7 Difficulties associated with anabolic steroid research 1.-24 1-25 1.8 The polydrug abuse Phenomenon 1.9 The pharmacology of cocaine 1-26 1.10 Pteparations 1-28 1-29 1.11 Metabolism lll 1-30 1.
    [Show full text]
  • A Review of Palliative Therapies for Cancer- Associated Anorexia
    58 Review Article A hunger for hunger: a review of palliative therapies for cancer- associated anorexia Daniel S. Childs1, Aminah Jatoi2 1Department of Medicine, 2Department of Oncology, Mayo Clinic, Rochester, MN, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: DS Childs; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Aminah Jatoi, MD. Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: [email protected]. Abstract: Cancer-associated anorexia, or loss of appetite, is prevalent, distressing to patients and their families, and associated with poorer outcomes in patients with advanced cancer. A well-defined therapeutic strategy remains to be defined. We present here a review of appetite loss in cancer patients with a summary of how best to manage this symptom. Keywords: Loss of appetite, anorexia, appetite stimulants, cancer, nutrition Submitted Mar 05, 2018. Accepted for publication May 07, 2018. doi: 10.21037/apm.2018.05.08 View this article at: http://dx.doi.org/10.21037/apm.2018.05.08 Introduction of appetite is common among cancer patients. What are the implications of loss of appetite in patients Many patients with advanced, incurable cancer suffer with cancer? Importantly, cancer-associated loss of appetite from loss of appetite, herein referred to as anorexia. The is not a simple, isolated symptom. It often occurs in the prevalence of this symptom varies from study to study. presence of a multiplicity of other symptoms like pain, Reporting on data from the PreMiO Study that included fatigue, and weakness; however, even after accounting 1,952 cancer patients, Muscaritoli and others noted that for the effects of other variables, the presence of cancer- 40% of patients reported loss of appetite as per a validated associated anorexia was found to strongly influence patient questionnaire (1).
    [Show full text]